The mass action equation in pharmacology

British Journal of Clinical Pharmacology

Volumn 81, Issue 1, 2016, Pages 41-51

  Kenakin, Terry ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dose response; Mass action; Pharmacology; Receptor

Indexed keywords

ADSORPTION; AGONIST POTENCY; ALLOSTERISM; ANTAGONIST POTENCY; ARTICLE; CONFORMATION; DISSOCIATION CONSTANT; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENCY; EC50; INTRACELLULAR SIGNALING; LIGAND BINDING; MASS ACTION; MASS ACTION EQUATION; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; STOICHIOMETRY; ANIMAL; CHEMISTRY; DOSE RESPONSE; HUMAN; PHARMACOLOGY; PROBABILITY;

DRUG RECEPTOR; LIGAND;

ALLOSTERIC REGULATION; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; PHARMACOLOGY; PROBABILITY; PROTEIN CONFORMATION; RECEPTORS, DRUG;

EID: 84953245929     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12810     Document Type: Article

References (38)

1. Guldberg CM, Waage P. Studies concerning affinity. C. M. Forhandlinger: Videnskabs-Selskabet i Christiana 1864; 35.
2. Guldberg CM, Waage P. Concerning chemical affinity. Erdmann's J Prac Chem 1879; 127: 69-114.
3. Colquhoun D. Imprecision in presentation of binding studies. Trends Pharmacol Sci 1985; 6: 197.
4. Voss H-P, Donnell D, Bast A. Atypical molecular pharmacology of a new long acting β2-adrenoceptor agonist TA 2005. Eur J Pharmacol 1992; 227: 403-9.
5. Burgen ASV. Conformational changes and drug action. Fed Proc 1981; 40: 2723-8.
6. Fraunfelder H, Parak F, Young RD. Conformational substrates in proteins. Annu Rev Biophys Biophys Chem 1988; 17: 451-79.
7. Fraunfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991; 254: 1598-603.
8. Hilser J, Dowdy D, Oas TG, Freire E. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc Natl Acad Sci U S A 1998; 95: 9903-8.
9. Hilser VJ, Garcia-Moreno EB, Oas TG, Kapp G, Whitten ST. A statistical thermodynamic model of protein ensembles. Chem Rev 2006; 106: 1545-58.
10. Onaran HO, Costa T. Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci 1997; 812: 98-115.
11. Onaran HO, Scheer A, Cotecchia S, Costa T. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. In: The Pharmacology of Functional, Biochemical, and Recombinant Systems Handbook of Experimental Pharmacology, Vol. 148, eds Kenakin TP, Angus JA. Heidelberg: Springer, 2002; 217-80.
12. Kenakin TP, Onaran O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 2002; 23: 275-80.
13. Michaelis L, Menten ML. Die kinetic der invertinwirkung. Biochem Z 1913; 49: 333-69.
14. Black JW, Leff P. Operational models of pharmacological agonist. Proc R Soc Lond [Biol] 1983; 220: 141-62.
15. Black JW, Leff P, Shankley NP. (Appendix J. Wood) An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 1985; 84: 561-71.
16. Galandrin S, Bouvier M. Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006; 70: 1575-84.
17. Metra M, Dei Cas L, di Lenarda A, Poole-Wilson P. Betablockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 2004; 9: 123-30.
18. Kenakin TP. Agonist-receptor efficacy II: agonist-trafficking of receptor signals. Trends Pharmacol Sci 1995; 16: 232-8.
19. Kenakin T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol 2012; 13: 3.
20. Kenakin TP. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 2012; 165: 1659-69.
21. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr. Cardiorenal actions of TRV120027, a novel β- arrestin-biased ligand at the angiotensin II type one receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011; 4: 770-8.
22. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 2012; 5: 627-34.
23. Hill AV. The possible effects of the aggregation of the molecules of hæmoglobin on its dissociation curves. J Physiol 1910; 40 (Suppl.): iv-vii.
24. Langmuir I. The constitution and fundamental properties of solids and liquids. Part I Solids. J Am Chem Soc 1916; 38: 2221-95.
25. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci 2006; 27: 149-57.
26. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010; 62: 265-304.
27. Stockton JM, Birdsall NJM, Burgen ASV, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 23: 551-7.
28. Ehlert EJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988; 33: 187-94.
29. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah STA, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011; 477: 549-55.
30. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, DeVree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK. Structure of a nanobodystabilized active state of the β2 adrenoceptor. Nature 2011; 469: 175-80.
31. Mary S, Damian M, Louet M, Floquet N, Fehrentz J-A, Marie J, Martinez J, Banère J-L. Ligands and signaling proteins govern the conformational landscape explored by G protein-coupled receptor. Proc Natl Acad Sci U S A 2012; 109: 8304-9.
32. Yan F, Mosier PD, Westkaemper RB, Roth BL. Galphasubunits differentially alter the conformation and agonist affinity of k-opioid receptors. Biochem 2008; 47: 1567-78.
33. Black JW, Shankley NP. Interpretation of agonist affinity estimations: the question of distributed receptor states. Proc Roy Soc Lond B Biol Sci 1990; 240: 503-18.
34. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997; 51: 357-62.
35. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987; 41: 1051-64.
36. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010; 335: 572-9.
37. Kenakin TP. Efficacy at G protein coupled receptors. Annu Rev Pharmacol Toxicol 2002; 42: 349-79.
38. Kenakin TP. Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin Drug Disc 2006; 1: 635-52.